ArticleBMC anesthesiology2026
Median effective dose (ED50) of ciprofol combined with alfentanil for suppressing cervical dilation responses during hysteroscopy: a prospective Dixon up-and-down study.
Article in BMC anesthesiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCervical dilation during hysteroscopy induces significant nociceptive stimulation that may provoke somatic response and compromise procedural conditions. The optimal induction dose of ciprofol combined with alfentanil for suppressing cervical dilation responses remains unclear. This study aimed to determine the median effective dose (ED50) of ciprofol using the Dixon up-and-down method and to estimate ED95 using logistic regression.
methodsIn this prospective dose-finding study, adult patients undergoing elective hysteroscopy received alfentanil 7.4 μg/kg followed by ciprofol at sequentially adjusted doses (initial dose 0.40 mg/kg; step size 0.025 mg/kg). A positive response (failure) was defined as the occurrence of any somatic movement (body movement, perioral twitching, frowning, or restlessness) during cervical dilation. A negative response (success) was defined as complete absence of movement. Enrollment continued until seven crossover pairs were obtained. ED50 was calculated using the Dixon-Mood method. ED95 and 95% confidence intervals were estimated using logistic regression.
resultsThirty-two patients were included. The ED50 determined by the Dixon-Mood method was 0.397 mg/kg. Model-based regression analysis yielded an ED50 of 0.397 mg/kg (95% CI: 0.366-0.428 mg/kg) and an ED95 of 0.521 mg/kg (95% CI: 0.389-0.652 mg/kg). Two patients (6.3%) required transient jaw-thrust intervention; no assisted ventilation or serious adverse events occurred.
conclusionWhen combined with alfentanil 7.4 µg/kg, ciprofol provided dose-dependent suppression of cervical dilation responses during hysteroscopy, with an ED50 of 0.397 mg/kg and a model-based ED95 of 0.521 mg/kg.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.